WHWK CFO logs tax-related stock disposals

Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported broker-assisted dispositions of common stock primarily to cover tax obligations from vesting equity awards.

Accepted by SEC EDGAR 04/17/2026 - 04:53 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. Chief Financial Officer Scott M. Giacobello reported broker-assisted dispositions of common stock primarily to cover tax obligations from vesting equity awards. On April 15 and 16, he sold 77,000 shares at $3.86 and 141,600 shares at $4.13 per share, respectively. A footnote explains these represent sales to satisfy tax withholding obligations tied to restricted stock unit vesting, rather than discretionary open-market selling. After these transactions, he continues to hold 295,224 shares of common stock directly.

Insider Trade Summary

Net Seller: 218,600 shares

Net Sell 2 txns

Insider Giacobello Scott M.

Role CHIEF FINANCIAL OFFICER

Sold 218,600 shs ($882K)

Type	Security	Shares	Price	Value
Sale	Common Stock	141,600	$4.13	$585K
Sale	Common Stock	77,000	$3.86	$297K

Holdings After Transaction: Common Stock — 295,224 shares (Direct)

Footnotes (2)

1. F1. Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
2. F2. Includes an aggregate of 11,822 shares of Common Stock acquired between November 14, 2022 and November 15, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

Key Figures

Shares sold April 15: 77,000 shares at $3.86 Shares sold April 16: 141,600 shares at $4.13 Total shares disposed: 218,600 shares +3 more

6 metrics

Shares sold April 15 77,000 shares at $3.86 Common stock sale on 2026-04-15

Shares sold April 16 141,600 shares at $4.13 Common stock sale on 2026-04-16

Total shares disposed 218,600 shares Aggregate of reported sales in this Form 4

Post-transaction holdings 295,224 shares Directly held common stock after April 16 transaction

ESPP shares acquired 11,822 shares Acquired between November 14, 2022 and November 15, 2025 under 2021 ESPP

Net buy/sell shares -218,600 shares Net sell direction across reported transactions

Key Terms

broker-assisted sale, restricted stock units, 2021 Employee Stock Purchase Plan, Common Stock

4 terms

broker-assisted sale financial

"Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations"

restricted stock units financial

"tax withholding obligations in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2021 Employee Stock Purchase Plan financial

"acquired between November 14, 2022 and November 15, 2025 under the Issuer's 2021 Employee Stock Purchase Plan"

Common Stock financial

"Includes an aggregate of 11,822 shares of Common Stock acquired"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Whitehawk Therapeutics (WHWK) CFO Scott Giacobello report in this Form 4?

He reported broker-assisted dispositions of Whitehawk Therapeutics common stock. The Form 4 shows sales mainly to satisfy tax withholding obligations from vesting restricted stock units, not discretionary portfolio sales, and confirms he still directly holds 295,224 shares after the transactions.

How many Whitehawk Therapeutics (WHWK) shares did the CFO dispose of?

He disposed of a total of 218,600 common shares across two days. The Form 4 lists 77,000 shares sold at $3.86 per share and 141,600 shares sold at $4.13 per share, executed as broker-assisted trades to cover tax obligations on equity vesting.

What prices were received for the WHWK shares sold by the CFO?

The reported sales occurred at two distinct prices. On April 15, 77,000 shares were sold at $3.86 per share, and on April 16, 141,600 shares were sold at $4.13 per share, according to the Form 4 transaction detail for Whitehawk Therapeutics common stock.

Why did the Whitehawk Therapeutics (WHWK) CFO sell these shares?

A footnote explains the sales were to satisfy tax withholding obligations. Specifically, they were broker-assisted sales connected to the vesting of restricted stock units, indicating a tax-related, mechanistic disposition rather than a discretionary open-market reduction of his investment position.

How many WHWK shares does the CFO hold after these transactions?

Following the reported dispositions, the CFO directly holds 295,224 shares of Whitehawk Therapeutics common stock. This post-transaction holding figure is shown in the Form 4 and reflects his continuing equity stake after covering tax obligations from vesting restricted stock units.

What additional WHWK shares has the CFO acquired through employee plans?

A footnote states he acquired 11,822 shares under the 2021 Employee Stock Purchase Plan. These purchases occurred between November 14, 2022 and November 15, 2025, adding to his overall position in Whitehawk Therapeutics through regular employee share purchase participation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Giacobello Scott M.

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		S(1)		77,000	D	$3.86	436,824(2)	D
Common Stock	04/16/2026		S(1)		141,600	D	$4.13	295,224	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

2. Includes an aggregate of 11,822 shares of Common Stock acquired between November 14, 2022 and November 15, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

	/s/ Stephen Rodin, as Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)